MIME-Version: 1.0
Date: Tue, 27 Jul 2021 18:59:41 +0000
References: <CACNgykO83f88gKGY99Fkqfo-BzU67LpVdQmZuntdj74OexJd+g@mail.gmail.com>
	<CAFvsdryLRnbDLGXQURKpEy9ut3g8cYMQFArqXjaA7H8dXyGOTw@mail.gmail.com>
	<CACNgykN3n50aONuykLu3=rs_Ap7bBJYYbRVTA9YPM0XsDiOENw@mail.gmail.com>
In-Reply-To: <CACNgykN3n50aONuykLu3=rs_Ap7bBJYYbRVTA9YPM0XsDiOENw@mail.gmail.com>
Message-ID: <CACNgykPs=aPX17C1mfQCqOndHOsBiuA2TLchx6Os0cWCHd0pDg@mail.gmail.com>
Subject: Re: Solving Diabetes, Heart Disease, and Obesity. Why not?
From: Josh Klein <josh@josh.is>
To: Phillip Barlag <phillipbarlag@gmail.com>
Cc: Joshua William Klein <josh@josh.is>
Content-Type: multipart/alternative; boundary="00000000000002e18605c81f79a4"

--00000000000002e18605c81f79a4
Content-Type: text/plain; charset="UTF-8"
Content-Transfer-Encoding: quoted-printable

Hey Phillip,

I'm hoping you're having a good sabbatical! Just circling back to see if
this is worth surfacing as something more formal for W50, or if you think
I'd be better off reaching out to some contacts (such as at Novo Nordisk,
for example)?

Gratefully,
Josh

=E1=90=A7

On Wed, Jul 7, 2021 at 5:06 PM Josh Klein <josh@josh.is> wrote:

> Thanks so much, Phillip! You may say "if there's a next time" now, but
> just wait until the pain has faded from your memory...
>
> An ideal partner is one who will sign a single agreement for exclusive
> licensing rights in exchange for a mix of investment and % of proceeds, a=
s
> well as a chance to repeat the trial for other categories. Extra points i=
f
> they can turn these insights into products at scale and can quickly
> activate a very large cohort for the trial.
>
> At its heart, the proposition here is that we can run a scaled trial to
> quickly figure out what design elements will turn new data types into
> behavior change in end users. That's pretty powerful when you look at the
> broad assortment of new medical sensor tech coming out now; there's lots =
of
> potential players who could benefit but I'd expect a J&J, Novo Nordisk, o=
r
> similar would be the place to start.
>
> Before any of that, though, is there a more formal opportunity for W50
> here? I'm flattered (and interested!) in any introductions you think are
> useful, but am also really grateful to W50 and would love to see them pul=
l
> off another Nike+Apple style agreement. I know W50 is changing a lot thes=
e
> days - is that a conversation worth having, or should I just shut my mout=
h
> and gladly accept an introduction or two?
>
> Also, Sabbatical? Is this book recovery?
>
> Thanks again,
> Josh
>
>
>
> =E1=90=A7
>
> On Wed, Jul 7, 2021 at 11:06 AM Phillip Barlag <phillip.barlag@world50.co=
m>
> wrote:
>
>> yooooo. Good morning. The book is...okay. I think it's gone well but it'=
s
>> had a little post-launch lull (to be expected). The big issue now is
>> getting people to write reviews. Next time around, I am going to write 2=
00
>> of them, put them in a google doc, and give people the link. Tell them t=
o
>> cut and paste. Well, who knows if there is a next time....
>>
>> I did not know about your diagnosis and experience with diabetes. I am
>> sorry you've been through it, and not at all surprised you've been able =
to
>> do such amazing things. Any relationship I have is yours. Do you have a
>> sense for the ideal partner? Is it Novo Nordisk, for example? Who within=
 a
>> company? I know a few people here and there, as, I am sure, do some of m=
y
>> colleagues.
>>
>> I logged into my email this morning as one last check before sabbatical.
>> I've CCed my personal email. I would like to keep the thread going. When
>> you reply to this, drop W50 email off and we will continue "over there."
>> Thanks Josh.
>>
>> On Wed, Jul 7, 2021 at 4:53 AM Josh Klein <josh@josh.is> wrote:
>>
>>> How goes the book selling world? I've been really enjoying your missive=
s
>>> - believe me, I'm taking notes!
>>>
>>> I've got a venture I need your take on as it involves W50. Not sure if
>>> you recall, but a few years ago I was diagnosed as diabetic. Long story
>>> short, I reversed it by using the same Continuous Glucose Monitoring (C=
GM)
>>> devices which were (ironically) causing my blood sugar to spike in the
>>> first place.
>>>
>>> Now I want to use that experience to launch a large-scale trial
>>> <https://docs.google.com/presentation/d/1epRbFnMTK4xpSTnTGZkn-Uh1asBvSm=
OkelWdz8F-K_g/edit#slide=3Did.g94ec82ae12_0_281>
>>> to determine how to help anybody avoid diabetes, obesity, and heart dis=
ease
>>> (all lifestyle diseases for which spiking glucose is a predicate.) I've=
 got
>>> the right partners, software, and procedures and now I need a large
>>> corporate partner who can sponsor the trial and license the results to =
make
>>> real, world-changing products at scale.
>>>
>>> I know World 50 was instrumental in making the Nike + Apple partnership
>>> happen. I'd like to set this up as another example of that, instead of =
just
>>> contacting target companies myself.
>>>
>>> Am I smoking crack here, or is this the sort of thing W50 would like to
>>> help with?
>>>
>>> All best,
>>> Josh
>>> =E1=90=A7
>>>
>>
>>
>> --
>> Phillip Barlag :: *World 50*
>>
>> +1 617 462 9192
>> phillip.barlag@world50.com
>>
>> *Download the World 50 app*
>> iOS <https://itunes.apple.com/us/app/id668135651?mt=3D8> | Android
>> <https://play.google.com/store/apps/details?id=3Dcom.w50.members>
>>
>

--00000000000002e18605c81f79a4
Content-Type: text/html; charset="UTF-8"
Content-Transfer-Encoding: quoted-printable

<div dir=3D"ltr">Hey Phillip,<div><br></div><div>I&#39;m hoping you&#39;re =
having a good sabbatical! Just circling back to see if this is worth surfac=
ing as something more formal for W50, or if you think I&#39;d be better off=
 reaching out to some contacts (such as at Novo Nordisk, for example)?</div=
><div><br></div><div>Gratefully,<br></div><div>Josh</div><div><br></div></d=
iv><div hspace=3D"streak-pt-mark" style=3D"max-height:1px"><img alt=3D"" st=
yle=3D"width:0px;max-height:0px;overflow:hidden" src=3D"https://mailfoogae.=
appspot.com/t?sender=3Daam9zaEBqb3NoLmlz&amp;type=3Dzerocontent&amp;guid=3D=
1b69f375-3e53-4ac6-8ce4-68bb10ddcc6b"><font color=3D"#ffffff" size=3D"1">=
=E1=90=A7</font></div><br><div class=3D"gmail_quote"><div dir=3D"ltr" class=
=3D"gmail_attr">On Wed, Jul 7, 2021 at 5:06 PM Josh Klein &lt;<a href=3D"ma=
ilto:josh@josh.is">josh@josh.is</a>&gt; wrote:<br></div><blockquote class=
=3D"gmail_quote" style=3D"margin:0px 0px 0px 0.8ex;border-left:1px solid rg=
b(204,204,204);padding-left:1ex"><div dir=3D"ltr">Thanks so much, Phillip! =
You may say &quot;if there&#39;s a next time&quot; now, but just wait until=
 the pain has faded from your memory...=C2=A0<div><br></div><div>An ideal p=
artner is one who will sign a single agreement for exclusive licensing righ=
ts in exchange for a mix of investment and % of proceeds, as well as a chan=
ce to repeat the trial for other categories. Extra points if they can turn =
these insights into products at scale and can quickly activate a very large=
 cohort for the trial.=C2=A0</div><div><br></div><div>At its heart, the pro=
position here is that we can run a scaled trial to quickly figure out what =
design elements will turn new data types into behavior change in end users.=
 That&#39;s pretty powerful when you look at the broad assortment of new me=
dical sensor tech coming out now; there&#39;s lots of potential players who=
 could benefit but I&#39;d expect a J&amp;J, Novo Nordisk, or similar would=
 be the place to start.</div><div><br></div><div>Before any of that, though=
, is there a more formal opportunity for W50 here? I&#39;m flattered (and i=
nterested!) in any introductions you think are useful, but am also really g=
rateful to W50 and would love to see them pull off another Nike+Apple style=
 agreement. I know W50 is changing a lot these days - is that a conversatio=
n worth having, or should I just shut my mouth and gladly accept an introdu=
ction or two?</div><div><br></div><div>Also, Sabbatical? Is this book recov=
ery?</div><div><br></div><div>Thanks again,<br>Josh</div><div><br></div><di=
v><br></div><div></div><div><br></div></div><div hspace=3D"streak-pt-mark" =
style=3D"max-height:1px"><img alt=3D"" style=3D"width: 0px; max-height: 0px=
; overflow: hidden;" src=3D"https://ci6.googleusercontent.com/proxy/QIiJcdE=
yyzdNUErc1Czy7wJKKFaYCj9hsN2lVEsqRI7fI5OSkxC7RTCa3x2gesLwNQqNx_zSTxfMajveOT=
no2Um2uHxMgA9VNwQ8G_OpJS9BvVKD6_Vo24BSxcLmNB58fYqbYk3WgYe68fx1QTrDg-z__ci8p=
NOh3ADlHju2FaVhPrYAdLzF=3Ds0-d-e1-ft#https://mailfoogae.appspot.com/t?sende=
r=3Daam9zaEBqb3NoLmlz&amp;type=3Dzerocontent&amp;guid=3Dbdd8a2b9-c992-47b6-=
ac0d-97d49fda239f"><font color=3D"#ffffff" size=3D"1">=E1=90=A7</font></div=
><br><div class=3D"gmail_quote"><div dir=3D"ltr" class=3D"gmail_attr">On We=
d, Jul 7, 2021 at 11:06 AM Phillip Barlag &lt;<a href=3D"mailto:phillip.bar=
lag@world50.com" target=3D"_blank">phillip.barlag@world50.com</a>&gt; wrote=
:<br></div><blockquote class=3D"gmail_quote" style=3D"margin:0px 0px 0px 0.=
8ex;border-left:1px solid rgb(204,204,204);padding-left:1ex"><div dir=3D"lt=
r">yooooo. Good morning. The book is...okay. I think it&#39;s gone well but=
 it&#39;s had a little post-launch lull (to be expected). The big issue now=
 is getting people to write reviews. Next time around, I am going to write =
200 of them, put them in a google doc, and give people the link. Tell them =
to cut and paste. Well, who knows if there is a next time....<div><br></div=
><div>I did not know about your=C2=A0diagnosis and experience with diabetes=
. I am sorry you&#39;ve been through it, and not at all surprised you&#39;v=
e been able to do such amazing things. Any relationship I have is yours. Do=
 you have a sense for the ideal partner? Is it Novo Nordisk, for example? W=
ho within a company? I know a few people here and there, as, I am sure, do =
some of my colleagues.=C2=A0</div><div><br></div><div>I logged into my emai=
l this morning as one last check before sabbatical. I&#39;ve CCed=C2=A0my p=
ersonal email. I would like to keep the thread going. When you reply to thi=
s, drop W50 email off and we will continue &quot;over there.&quot; Thanks J=
osh.=C2=A0</div></div><br><div class=3D"gmail_quote"><div dir=3D"ltr" class=
=3D"gmail_attr">On Wed, Jul 7, 2021 at 4:53 AM Josh Klein &lt;<a href=3D"ma=
ilto:josh@josh.is" target=3D"_blank">josh@josh.is</a>&gt; wrote:<br></div><=
blockquote class=3D"gmail_quote" style=3D"margin:0px 0px 0px 0.8ex;border-l=
eft:1px solid rgb(204,204,204);padding-left:1ex"><div dir=3D"ltr">How goes =
the book selling world? I&#39;ve been really enjoying your missives - belie=
ve me, I&#39;m taking notes!<br><br>I&#39;ve got a venture I need your take=
 on as it involves W50. Not sure if you recall, but a few years ago I was d=
iagnosed as diabetic. Long story short, I reversed it by using the same Con=
tinuous Glucose Monitoring (CGM) devices which were (ironically) causing my=
 blood sugar to spike in the first place. <br><br>Now I want to use that ex=
perience to launch a <a href=3D"https://docs.google.com/presentation/d/1epR=
bFnMTK4xpSTnTGZkn-Uh1asBvSmOkelWdz8F-K_g/edit#slide=3Did.g94ec82ae12_0_281"=
 target=3D"_blank">large-scale trial</a> to determine how to help anybody a=
void diabetes, obesity, and heart disease (all lifestyle diseases for which=
 spiking glucose is a predicate.) I&#39;ve got the right partners, software=
, and procedures and now I need a large corporate partner who can sponsor t=
he trial and license the results to make real, world-changing products at s=
cale.<br><br>I know World 50 was instrumental in making the Nike + Apple pa=
rtnership happen. I&#39;d like to set this up as another example of that, i=
nstead of just contacting target companies myself. <br><br>Am I smoking cra=
ck here, or is this the sort of thing W50 would like to help with?<br><br>A=
ll best,<br>Josh<br></div><div hspace=3D"streak-pt-mark" style=3D"max-heigh=
t:1px"><img alt=3D"" style=3D"width: 0px; max-height: 0px; overflow: hidden=
;" src=3D"https://ci6.googleusercontent.com/proxy/GLZQBUrZd_rI-Avj7iWCeFXNK=
qRzPI9ABeOp-jxCuyWrTrHsiEGO-DbybJnCZmm2s5JIsW4lzHrb2DuG8-gjHBSTFPPFTb5B_Rn-=
eJm_-huICDuxK53tJZ6gjRvz1_hxNlVcYLYkJpUtCgvbrk3iozJkW8OcMsRTYq6IwKeMr6DA-9y=
q5DMO=3Ds0-d-e1-ft#https://mailfoogae.appspot.com/t?sender=3Daam9zaEBqb3NoL=
mlz&amp;type=3Dzerocontent&amp;guid=3D0828fdf3-ad16-4530-9177-b339da89b63b"=
><font color=3D"#ffffff" size=3D"1">=E1=90=A7</font></div>
</blockquote></div><br clear=3D"all"><div><br></div>-- <br><div dir=3D"ltr"=
><div dir=3D"ltr"><div><div dir=3D"ltr"><div dir=3D"ltr"><div dir=3D"ltr"><=
div dir=3D"ltr"><div dir=3D"ltr"><font face=3D"arial, helvetica, sans-serif=
" color=3D"#999999" size=3D"1">Phillip Barlag ::=C2=A0<b>World 50</b></font=
></div><div dir=3D"ltr"><div><font face=3D"arial, helvetica, sans-serif" co=
lor=3D"#999999" size=3D"1"><br></font></div><div><font face=3D"arial, helve=
tica, sans-serif" color=3D"#999999" size=3D"1">+1 617 462 9192=C2=A0</font>=
</div><div><font face=3D"arial, helvetica, sans-serif" color=3D"#999999" si=
ze=3D"1"><a href=3D"mailto:phillip.barlag@world50.com" style=3D"color:rgb(1=
7,85,204)" target=3D"_blank">phillip.barlag@world50.com</a>=C2=A0</font></d=
iv><div><font face=3D"arial, helvetica, sans-serif" color=3D"#999999" size=
=3D"1"><br></font></div><div><div><font size=3D"1" color=3D"#999999"><b>Dow=
nload the World 50 app</b></font></div><div><font size=3D"1" color=3D"#9999=
99"><a href=3D"https://itunes.apple.com/us/app/id668135651?mt=3D8" style=3D=
"color:rgb(17,85,204)" target=3D"_blank">iOS</a>=C2=A0|=C2=A0<a href=3D"htt=
ps://play.google.com/store/apps/details?id=3Dcom.w50.members" style=3D"colo=
r:rgb(17,85,204)" target=3D"_blank">Android</a></font></div></div></div></d=
iv></div></div></div></div></div></div>
</blockquote></div>
</blockquote></div>

--00000000000002e18605c81f79a4--